CAVHANZATM (nilotinib) Orally Disintegrating Tablets: A New, FDA-approved Treatment Offering PPI and H2RA Flexibility for Ph+ CML Patients1

CAMBRIDGE, England--(BUSINESS WIRE)--Cycle Pharmaceuticals (Cycle) announces the FDA approval of CAVHANZA (nilotinib) Orally Disintegrating Tablets. Launching soon, the CAVHANZA formulation is specifically designed to improve solubility and dissolution rate, enabling maintained bioavailability with concomitant use of acid-reducing agents such as proton pump inhibitors (PPIs) and/or H2 antagonists (H2RAs) without timing restrictions.1 This will be a first in the nilotinib market, addressing a kn